The BioPharm Brief: Pills, Skin, and Biosimilars

Sep 30, 10:07 PM
Headliner
Share
Subscribe

Real-world data show weight loss after switching to the Wegovy pill, Lilly reports positive hand and foot atopic dermatitis data, and Teva wins FDA approval for a Xgeva biosimilar.

Share
Subscribe
Next
The BioPharm Brief: Deals, Data, and a $2 Billion Bet
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief